SecBot SecBot

DWTX

Dogwood Therapeutics, Inc.
Nasdaq· Pharmaceutical Preparations· Inc. DE· CIK 0001818844 Biotech & Drug Discovery
$1.12 +0.00 (+0.00%)
Oct 23 4:00 PM ET · prev $1.12
Market cap
$38.1M
Nano cap
Median target
$15.00
+1239% · range $12.00–15.00
Next earnings
Nov 4
in 9 days · EPS est. −$0.15
1 year
−81.0%
from $5.88 · Oct 24
30 days
−21.7%
from $1.43
52-week range
$1.12–6.82
−84% from high · low Oct 22
Avg volume 20D
75.5K
Oct 19 spike 226.2K
Short interest
38.9K
≈0.1% of shares · −47.6%
Days to cover
1.0
at average volume
Insider net
$0
no open-market trades · 12 mo
New fund stakes
0
Q2 2026 13F · 0 exits
Filing reports
5
analyzed by SecBot
SecBot read MIXED 4 reports · 90 days
Balance 1 bearish · 0 bullish · 2 mixed · 1 neutral oldest → newest, height = score
Avg score ·High conf. 3/4 ·Next Earnings date, Nov 4, 2026
Strongest MIXED Dogwood Therapeutics announced a $5 million private placement with its largest shareholder, Sealbond Limited…
All reports →

Price

Daily candles with volume. Pins mark insider trades, rating changes, 13F stakes, reports, catalysts and short-interest jumps.

Signal stack

Where each data set points today.

  • InsidersNO TRADES

    No open-market buys or sells in 12 months. Recent filings are awards, exercises and tax withholding.

  • InstitutionsMIXED

    Q2 2026: 1 added (0 new), 1 trimmed or exited.

  • EstimatesRISING

    Current-quarter EPS estimate −$0.210 → −$0.155 over 90 days. 0 up, 2 down in 30 days.

  • Short sellersCOVERING

    Short interest −47.6% to 38.9K shares. 1.0 days to cover, ≈0.1% of shares.

  • TrendDOWNTREND

    37% below its 50-day average. New closing low $1.12 on Oct 23.

Who's buying

13F· Q2 2026
0
new positions
0
exits
FundMoveSharesValue
BlackRock, Inc.DOUBLED28,546$46.0K
UBS Group AGTRIM1,860$3.0K
GEODE CAPITAL MANAGEMENT, LLCDOUBLED79,434$167.6K
UBS Group AGDOUBLED7,085$14.9K
VANGUARD GROUP INCADD29,955$124.6K
BANK OF AMERICA CORP /DE/DOUBLED9,415$39.2K
BNP PARIBAS FINANCIAL MARKETSNEAR_EXIT2$8.00
VANGUARD GROUP INCADD22,179$170.8K

Quarterly 13F filings are due 45 days after each quarter ends.

The Street

last action May 2026
12-month targets · 3 analysts

Price is below the lowest target. Median implies +1239%.Targets as of Oct 26, 2026.

Recent actions
DateFirmActionRating
May 19, 2026HC Wainwright & Co.
REITERATE
REITERATEBuy

Insider ledger

Form 4
$0
open-market buys or sells · 12 mo
DateInsiderTypeValue
Jun 16, 2026
Keefer David R
Director
AWARD16,800 sh
Jun 16, 2026
Whitley Richard James
Director
AWARD16,800 sh
Jun 16, 2026
Thomas John C
Director
AWARD16,800 sh
Jun 16, 2026
De La Rosa Abel
Director
AWARD16,800 sh
Mar 5, 2026
Duncan Gregory Scott
CHIEF EXECUTIVE OFFICER
AWARD330,000 sh
Mar 5, 2026
Grosswald Ralph
SVP OF OPERATIONS
AWARD82,500 sh
Mar 5, 2026
Gendreau Roger Michael
CHIEF MEDICAL OFFICER
AWARD82,500 sh
Mar 5, 2026
Walsh Angela
Chief Financial Officer
AWARD82,500 sh

Earnings setup

Estimates
Nov 4
reports in 9 days
−$0.15
EPS estimate, this quarter
+26%
estimate change, 90 days
0↑ 2↓
revisions, 30 days
Current-quarter EPS estimate
PeriodEPS est.Range30D rev.Revenue
Current Q-$0.15-$0.16–-$0.15-8.1%$0.00
Next Q-$0.16-$0.16–-$0.16-9.1%$0.00
Current FY-$0.88-$0.95–-$0.80-49.6%$0.00
Next FY-$0.64-$0.78–-$0.47+2.6%$0.00

Short side

FINRA· Sep 30, 2026
38,895
shares short
-47.6%
vs prior settlement
1.0
days to cover
≈0.1%
of shares outstanding
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Oct 21, 2026 SEC
Sealbond Ltd, the majority owner of Dogwood Therapeutics, filed Amendment No. 3 to its Schedule 13D, reporting a new…
SC 13D/A — Impact 4/10
Oct 19, 2026 SEC
Dogwood Therapeutics announced a $5 million private placement with its largest shareholder, Sealbond Limited (a…
8-K — Impact 6/10
Oct 19, 2026 Press
Dogwood Therapeutics announced a $5M private placement from its largest shareholder, CK Life Sciences, at $1.22/share…
Impact 5/10
Oct 19, 2026 Offering
Dogwood Announces $5 Million Private Placement with CK Life Sciences Int’l., (Holdings) Inc.
- Largest Shareholder Increases Position as Dogwood Advances Halneuron® Toward Topline Phase 2b Data
Aug 13, 2026 SEC
Dogwood Therapeutics reported Q2 2026 net loss of $11.5M ($0.34/share) vs $3.8M ($1.99/share) in Q2 2025, driven by a…
8-K — Impact 6/10
Jun 30, 2026 Inst.
BlackRock, Inc. — DOUBLED
28,546 shares ($46.0K)
Jun 30, 2026 Inst.
UBS Group AG — TRIM
1,860 shares ($3.0K)
Jun 16, 2026 Insider
Keefer David R was granted 16,800 shares
Director
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
Upcoming
Nov 4, 2026
Earnings date
DWTX Q3 2026 Earnings Scheduled — 2026-11-04
Recent
Oct 19, 2026
Offering
Dogwood Announces $5 Million Private Placement with CK Life Sciences Int’l., (Holdings) Inc.
- Largest Shareholder Increases Position as Dogwood Advances Halneuron® Toward Topline Phase 2b Data Readout in November 2026 - - Expected Proceeds…
Oct 6, 2026
Press release
Dogwood to Participate in the 2026 Maxim Growth Summit
ATLANTA, Oct. 06, 2026 (GLOBE NEWSWIRE) -- Dogwood Therapeutics, Inc. (Nasdaq: DWTX) (the “Company”), a company that focuses on developing…
Aug 17, 2026
Press release
Dogwood to Host Virtual KOL Event to Discuss Halneuron® for the Treatment of Chemotherapy Induced Neuropathic Pain on September 1, 2026
ALPHARETTA, Ga., Aug. 17, 2026 (GLOBE NEWSWIRE) -- Dogwood Therapeutics, Inc. (Nasdaq: DWTX) (“Dogwood” or the “Company”), a company that focuses on…
Aug 13, 2026
Earnings
Dogwood Therapeutics Announces Second Quarter 2026 Financial Results
- Halneuron ® Phase 2b trial in Chemotherapy Induced Neuropathy on track for top-line results in fall 2026, 217 patients enrolled –
Aug 11, 2026
Earnings date
DWTX Q2 2026 Earnings Scheduled — 2026-08-11

SecBot reports

5 filings · 4 press releases · 2 bullish · 1 bearish · 1 mixed · 1 neutral
All DWTX filing & press-release reports (9)